Capricor Therapeutics (CAPR) Change in Acquisitions & Divestments (2013 - 2026)

Capricor Therapeutics' Change in Acquisitions & Divestments history runs 13 years deep, the most recent figure standing at $31.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 28.27% year-over-year to $31.0 million in Q1 2026; TTM through Mar 2026 was $248.4 million, a 120.52% increase from a year earlier, with the FY2025 full-year figure at $260.6 million, up 177.83% from the prior year.
• Change in Acquisitions & Divestments eased to $31.0 million in Q1 2026 per CAPR's latest filing, from $63.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $78.2 million in Q3 2025 and bottomed at $14.0 million in Q2 2022.
• The 5-year median for Change in Acquisitions & Divestments is $30.5 million (2022), against an average of $35.8 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 48.86% in 2023 and surged 278.14% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $38.4 million in 2022, then slumped by 48.86% to $19.6 million in 2023, then declined by 14.89% to $16.7 million in 2024, then jumped by 278.14% to $63.2 million in 2025, then tumbled by 50.96% to $31.0 million in 2026.
• Per Business Quant, the three latest CAPR Change in Acquisitions & Divestments figures stand at $31.0 million (Q1 2026), $63.2 million (Q4 2025), and $78.2 million (Q3 2025).